<DOC>
	<DOCNO>NCT02433795</DOCNO>
	<brief_summary>This study conduct evaluate efficacy Bendamustine Plus Rituximab ( BR ) patient relapse progressive Marginal Zone B-cell Lymphoma ( MZBCL ) .</brief_summary>
	<brief_title>Bendamustine Plus Rituximab ( BR ) Relapsed Progressive Marginal Zone B-cell Lymphoma ( MZBCL )</brief_title>
	<detailed_description>Multi-center trial , Phase II , non-randomized , open-label , single-arm study combine therapy bendamustine rituximab patient MZBCL relapse progressive prior chemotherapy chemo-radiotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Histologically confirm CD20positive nodal extranodal MZBCL 2 . MZBCL patient relapse progress : At least one maximum four prior line chemotherapy During last chemotherapy radiotherapy Without progression within 6 month last dose rituximabbased regimen 3 . Patients age â‰¥ 18 year 4 . ECOG PS 02 5 . At least one bidimensionally measurable disease 6 . Adequate hematologic , renal , hepatic function 7 . Women childbearing potential use two appropriate method contraception study 8 . Written inform consent 1 . Not inclusion criterion meet . 2 . Prior chemotherapy within 4 week radiotherapy within 6 week 3 . Corticosteroids last 28 day except chronic administration prednisolone dose &lt; 20mg/day indication lymphomas 4 . Evidence CNS involvement lymphomas 5 . Active HBV/HCV infection , know HIV infection 6 . Prior diagnosis cancer within 5 year , except cervical intraepithelial neoplasia type 1 , localize nonmelanoma skin cancer , small differentiate thyroid cancer 7 . Serious concurrent disease : 8 . Patients pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Marginal zone B-cell lymphoma</keyword>
	<keyword>bendamustine plus rituximab</keyword>
</DOC>